Φορτώνει......
Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab
Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil activation, and blocks IgE binding to CD23 on B cells...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Biol Chem |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society for Biochemistry and Molecular Biology
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5473249/ https://ncbi.nlm.nih.gov/pubmed/28438838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.M117.776476 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|